A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia

Trial Profile

A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Vadastuximab talirine (Primary) ; Azacitidine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 25 Jun 2017 Results (n=53) of 33A+HMA cohort, presented at the 22nd Congress of the European Haematology Association
    • 19 Jun 2017 According to a company media release, Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials based on unfavourable results obtained in the phase III CASCADE trial.
    • 05 Apr 2017 Results of a biomarker analysis evaluating assessment of myeloblast CD33 receptor occupancy by vadastuximab talirine in patients with acute myeloid leukemia, presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top